Skip to main content

Table 1 Study Population characteristics, stratified by BNP reduction ≥25%, with p-value for difference between groups

From: Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score

  All patients (n = 202) BNP reduction < 25% (n = 78) BNP reduction ≥ 25% (n = 124) P-value
Male gender 157 (78%) 61 (78%) 96 (77%) 1.0
Age, (years) (median IQR) 71 (14) 72 (14) 69 (13) 0.14
LV ejection fraction (mean ± SD) 27 ± 7 27 ± 6 27 ± 8 0.92
LVESV (mean ± SD) 158 ± 68 148 ± 73 164 ± 65 0.09
QRS duration (ms, median IQR) 161 ± 23 154 ± 23 166 ± 22 < 0.001
Ischemic cardiomyopathy 100 (50%) 38 (49%) 62 (50%) 0.89
Hypertension 121 (60%) 47 (60%) 74 (60%) 1.0
Diabetes 50 (25%) 21 (27%) 29 (23%) 0.62
Atrial Fibrillation 91 (45%) 37 (47%) 54 (44%) 0.66
Previous CABG 52 (26%) 22 (28%) 30 (24%) 0.62
LBBB 129 (64%) 42 (54%) 87 (70%) 0.02
LBBB > 150 msec 148 (73%) 46 (59%) 102 (82%) 0.01
NYHA class III-IV 151 (75%) 55 (71%) 96 (77%) 0.32
ACEi or ARB use 179 (89%) 69 (89%) 110 (89%) 1.0
Loop diuretic use 147 (73%) 60 (77%) 87 (70%) 0.33
Anticoagulant use 91 (45%) 34 (44%) 57 (46%) 0.77
Digoxin use 27 (13%) 12 (15%) 15 (12%) 0.53
Beta-blocker use 176 (87%) 65 (83%) 111 (90%) 0.28
Creatinine pre implant (mg/dl) 1.12 (0.45) 1.20 (0.52) 1.08 (0.44) 0.05
CRT-D vs. CRT-Pacemaker 169 (84%) 63 (81%) 106 (86%) 0.44
NT-proBNP baseline (ng/L median IQR) 1554 (3393) 1444 (3770) 1661 (2968) 0.31
  1. CABG coronary artery bypass surgery, CRT-D cardiac resynchronization therapy with defibrillator function, LBBB left bundle branch block, NYHA New York Heart Association, ACEi ACE-inhibitor, ARB angiotensin receptor blocker